P14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway

Cancer Research

Volumn 74, Issue 5, 2014, Pages 1371-1378

  Zerrouqi, Abdessamad ^a   Pyrzynska, Beata ^a,e   Brat, Daniel J ^b,d   Van Meir, Erwin G ^a,c,d  

^a Laboratory of Molecular Neuro oncology   (United States)

^b Pathology and Laboratory Medicine   (United States)

^c Departments of Hematology and Medical Oncology   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C JUN; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR SP1;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; GENE; GENE ACTIVATION; GENE FUNCTION; GENE LOSS; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; P14ARF GENE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TFPI2 GENE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; TUMOR THROMBUS; UPREGULATION;

GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; THROMBOPLASTIN; THROMBOSIS; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF; UP-REGULATION;

EID: 84896511397     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-1951     Document Type: Article

References (49)

1. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010;60: 166-93.
2. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004;64:920-7.
3. Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 2004;84:397-405.
4. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-48.
5. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-9.
6. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
7. Tohma Y, Gratas C, Van Meir EG, Desbaillets I, Tenan M, Tachibana O, et al. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol 1998;57:239-45.
8. Ogiichi T, Hirashima Y, Nakamura S, Endo S, Kurimoto M, Takaku A. Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. J Neurooncol 2000;46:1-9.
9. Rao LV, Rapaport SI, Bajaj SP. Activation of human factor VII in the initiation of tissue factor-dependent coagulation. Blood 1986;68: 685-91.
10. Rong Y, Belozerov VE, Tucker-Burden C, Chen G, Durden DL, Olson JJ, et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 2009;69:2540-9.
11. Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A 2010;107:2616-21.
12. Magnus N, Garnier D, Rak J. Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood 2010;116:815-8.
13. Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005;65:1406-13.
14. Xie TX, Aldape KD, Gong W, Kanzawa T, Suki D, Kondo S, et al. Aberrant NF-kappaB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factor. Int J Oncol 2008;33:5-15.
15. Lanir N, Aharon A, Brenner B. Procoagulant and anticoagulant mechanisms in human placenta. Semin Thromb Hemost 2003;29: 175-84.
16. Takada H, Wakabayashi N, Dohi O, Yasui K, Sakakura C, Mitsufuji S, et al. Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer. Cancer Genet Cytogenet 2010;197:16-24.
17. Konduri SD, Srivenugopal KS, Yanamandra N, Dinh DH, Olivero WC, Gujrati M, et al. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human gliomacells. Oncogene 2003;22:4509-16.
18. Ribarska T, Ingenwerth M, Goering W, Engers R, Schulz WA. Epigenetic inactivation of the placentally imprinted tumor suppressor gene TFPI2 in prostate carcinoma. Cancer Genomics Proteomics 2010;7: 51-60.
19. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
20. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
21. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91:649-59.
22. Weber HO, Samuel T, Rauch P, Funk JO. Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene 2002;21:3207-12.
23. Kelly-Spratt KS, Gurley KE, Yasui Y, Kemp CJ. p19Arf suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. PLoS Biol 2004;2:E242.
24. Kamijo T, van de Kamp E, Chong MJ, Zindy F, Diehl JA, Sherr CJ, et al. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. Cancer Res 1999;59:2464-9.
25. Kamijo T, Bodner S, van de Kamp E, Randle DH, Sherr CJ. Tumor spectrum in ARF-deficient mice. Cancer Res 1999;59:2217-22.
26. Radfar A, Unnikrishnan I, Lee HW, DePinho RA, Rosenberg N. p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. Proc Natl Acad Sci U S A 1998;95:13194-9.
27. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, et al. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 2000;14:2358-65.
28. Zerrouqi A, Pyrzynska B, Febbraio M, Brat DJ, Van Meir EG. P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3. J Clin Invest 2012;122:1283-95.
29. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, et al. Frequent co-Alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999;9: 469-79.
30. Kaur B, Brat DJ, Devi NS, Van Meir EG. Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 2005;24:3632-42.
31. Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M,Hamou MF, et al. Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 2002;21: 4212-9.
32. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, et al. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 2001;61:4956-60.
33. Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, et al. Identification of a novel small-molecule inhibitor of the hypoxiainducible factor 1 pathway. Cancer Res 2005;65:605-12.
34. Kast C, Wang M, Whiteway M. The ERK/MAPK pathway regulates the activity of the human tissue factor pathway inhibitor-2 promoter. J Biol Chem 2003;278:6787-94.
35. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
36. Hube F, Reverdiau P, Iochmann S, Cherpi-Antar C, Gruel Y. Characterization and functional analysis of TFPI-2 gene promoter in a human choriocarcinoma cell line. Thromb Res 2003;109:207-15.
37. Kamei S, Kazama Y, Kuijper JL, Foster DC, Kisiel W. Genomic structure and promoter activity of the human tissue factor pathway inhibitor-2 gene. Biochim Biophys Acta 2001;1517:430-5.
38. Minden A, Lin A, Smeal T, Derijard B, Cobb M, Davis R, et al. c-Jun Nterminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-Activated protein kinases. Mol Cell Biol 1994;14:6683-8.
39. Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998;152:399-411.
40. Rong Y, Durden DL, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006;65:529-39.
41. Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci U S A 1994; 91:3353-7.
42. Rao CN, Lakka SS, Kin Y, Konduri SD, Fuller GN, Mohanam S, et al. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin Cancer Res 2001; 7:570-6.
43. Vaitkiene P, Skiriute D, Skauminas K, Tamasauskas A. Associations between TFPI-2 methylation and poor prognosis in glioblastomas. Medicina (Kaunas) 2012;48:345-9.
44. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR, et al. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 2005;24:850-8.
45. Jee CD, Kim MA, Jung EJ, Kim J, Kim WH. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur J Cancer 2009;45:1282-93.
46. Jia Y, Yang Y, Brock MV, Cao B, Zhan Q, Li Y, et al. Methylation of TFPI-2 is an early event of esophageal carcinogenesis. Epigenomics 2012;4:135-46.
47. Konduri SD, Osman FA, Rao CN, Srinivas H, Yanamandra N, Tasiou A, et al. Minimal and inducible regulation of tissue factor pathway inhibitor-2 in human gliomas. Oncogene 2002;21:921-8.
48. Karin M. The regulation of AP-1 activity by mitogen-Activated protein kinases. Philos Trans R Soc Lond B Biol Sci 1996;351:127-34.
49. Nishina H, Nakagawa K, Azuma N, Katada T. Activation mechanism and physiological roles of stress-Activated protein kinase/c-Jun NH2-Terminal kinase in mammalian cells. J Biol Regul Homeost Agents 2003;17:295-302.